NO981708L - FremgangsmÕte for deteksjon av cyklooksygenase-2 - Google Patents

FremgangsmÕte for deteksjon av cyklooksygenase-2

Info

Publication number
NO981708L
NO981708L NO981708A NO981708A NO981708L NO 981708 L NO981708 L NO 981708L NO 981708 A NO981708 A NO 981708A NO 981708 A NO981708 A NO 981708A NO 981708 L NO981708 L NO 981708L
Authority
NO
Norway
Prior art keywords
cyclooxygenase
detection
Prior art date
Application number
NO981708A
Other languages
English (en)
Other versions
NO981708D0 (no
Inventor
Peter C Isakson
Karen Seibert
John J Talley
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of NO981708D0 publication Critical patent/NO981708D0/no
Publication of NO981708L publication Critical patent/NO981708L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
NO981708A 1995-10-17 1998-04-16 FremgangsmÕte for deteksjon av cyklooksygenase-2 NO981708L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US568695P 1995-10-17 1995-10-17
PCT/US1996/016440 WO1997014679A2 (en) 1995-10-17 1996-10-16 Method of detecting cyclooxygenase-2

Publications (2)

Publication Number Publication Date
NO981708D0 NO981708D0 (no) 1998-04-16
NO981708L true NO981708L (no) 1998-06-10

Family

ID=21717184

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981708A NO981708L (no) 1995-10-17 1998-04-16 FremgangsmÕte for deteksjon av cyklooksygenase-2

Country Status (10)

Country Link
US (2) US6045773A (no)
EP (1) EP0859642A2 (no)
JP (1) JP2000510816A (no)
KR (1) KR19990064310A (no)
AU (1) AU716582B2 (no)
BR (1) BR9611047A (no)
CA (1) CA2234633A1 (no)
NO (1) NO981708L (no)
NZ (1) NZ322674A (no)
WO (1) WO1997014679A2 (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
USRE39708E1 (en) 1998-08-07 2007-06-26 Chiron Corporation Estrogen receptor modulators
DE60137512D1 (de) 2000-08-07 2009-03-12 Univ Vanderbilt Zusammensetzungen und verfahren zum nachweis und zur quantifizierung von cox-2-aktivität und 2-arachidonylglycerin-metaboliten
NZ530051A (en) * 2001-06-12 2006-12-22 Wellstat Therapeutics Corp Polycyclic oxy-aromatic acid derivatives for the treatment of metabolic disorders
KR20050034603A (ko) 2001-10-09 2005-04-14 3-디멘져널 파마슈티칼즈 인코오포레이티드 치환된 디페닐옥사졸, 이의 합성 및 이의 형광프로브로서의 용도
CN100378056C (zh) * 2001-10-10 2008-04-02 株式会社日立高新技术 发光性化合物及使用它们的标识试剂
US7329401B2 (en) * 2002-04-15 2008-02-12 The Regents Of The University Of California Cyclooxygenase-2 selective agents useful as imaging probes and related methods
US7314709B2 (en) * 2002-08-06 2008-01-01 Vanderbilt University Compositions and methods for detecting and quantifying COX-2 activity by lipoamino acid metabolism
AU2003270752A1 (en) * 2002-09-27 2004-04-19 King Pharmaceuticals Research And Development, Inc. A method to demonstrate the efficacy of pharmacological stress agent
TW200505446A (en) * 2003-01-17 2005-02-16 Fuj Isawa Pharmaceutical Co Ltd Inhibitor of cox
WO2005002293A2 (en) * 2003-06-25 2005-01-06 Vanderbilt University Cox-2-targeted imaging agents
US7112601B2 (en) * 2003-09-11 2006-09-26 Bristol-Myers Squibb Company Cycloalkyl heterocycles for treating hepatitis C virus
PL1742922T3 (pl) * 2004-04-01 2016-06-30 Zoetis Services Llc Krystaliczna pochodna pirazolu
TW200603792A (en) * 2004-04-23 2006-02-01 Pharmacia & Upjohn Co Llc Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
JP2007534702A (ja) * 2004-04-26 2007-11-29 バンダービルト・ユニバーシティ 胃腸毒性の低い治療薬としてのインドール酢酸、及びインデン酢酸誘導体
US20080138282A1 (en) * 2004-06-03 2008-06-12 The Trustees Of Columbia University In The City Of New York Radiolabeled Arylsulfonyl Compounds and Uses Thereof
JP2008526185A (ja) * 2005-01-04 2008-07-24 ノバルティス アクチエンゲゼルシャフト ヒトｆｐｐｓのｘ線構造およびｆｐｐｓ結合化合物を選択するための使用
AU2006214164B2 (en) 2005-02-17 2010-12-09 Synta Pharmaceuticals Corp. Isoxazole combretastin derivatives for the treatment of disorders
NL2000351C2 (nl) 2005-12-22 2007-09-11 Pfizer Prod Inc Estrogeen-modulatoren.
TW200803903A (en) * 2006-04-28 2008-01-16 Nihon Mediphysics Co Ltd Novel compound having affinity to amyloid
TW200808795A (en) * 2006-05-19 2008-02-16 Nihon Mediphysics Co Ltd Novel compound having affinity for amyloid
CN101528222A (zh) * 2006-06-19 2009-09-09 范德比尔特大学 用于诊断性和治疗性靶向cox-2的方法和组合物
EP2042501B1 (en) * 2006-06-21 2017-04-12 Nihon Medi-Physics Co., Ltd. Compound having affinity for amyloid
WO2008056481A1 (fr) * 2006-11-09 2008-05-15 Nihon Medi-Physics Co., Ltd. Agent d'imagerie de diagnostic radioactif
CN101535309A (zh) * 2006-11-17 2009-09-16 日本医事物理股份有限公司 对淀粉状蛋白具有亲和性的新化合物
NZ577511A (en) * 2006-11-30 2012-04-27 Nihon Mediphysics Co Ltd 2-Phenyl-imidazo[1,2-a]pyridine derivatives substituted with a radioactive halogen substituent
WO2008075522A1 (ja) * 2006-12-21 2008-06-26 Nihon Medi-Physics Co., Ltd. 放射性画像診断剤
JP2010516679A (ja) * 2007-01-19 2010-05-20 マリンクロット インコーポレイテッド 診断用および治療用シクロオキシゲナーゼ−２結合リガンド
TWI406674B (zh) 2007-02-13 2013-09-01 Nihon Mediphysics Co Ltd Method for manufacturing diagnostic radiographic diagnostic agents
BRPI0814542A2 (pt) 2007-07-12 2014-09-30 Tragara Pharmaceuticals Inc Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores
CN101903381A (zh) * 2007-10-24 2010-12-01 日本医事物理股份有限公司 对淀粉样蛋白具有亲和性的新化合物
EP2218463A1 (en) * 2007-10-30 2010-08-18 Nihon Medi-Physics Co., Ltd. Use of novel compound having affinity for amyloid, and process for production of the same
KR20100101576A (ko) * 2007-10-30 2010-09-17 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물의 사용 및 제조 방법
FR2926079B1 (fr) 2008-01-03 2012-12-28 Commissariat Energie Atomique Procede de preparation d'un derive de purine marque, ledit derive et ses utilisations
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
FI2247558T4 (fi) 2008-02-14 2024-09-19 Eli Lilly And Company Uusia kuvantamisaineita neurologisen toimintahäiriön toteamiseen
US8420052B2 (en) 2008-07-24 2013-04-16 Siemens Medical Solutions Usa, Inc. Imaging agents useful for identifying AD pathology
JP2012521988A (ja) 2009-03-23 2012-09-20 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド 神経学的障害を検知するためのイメージング剤
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
US9346803B2 (en) 2011-10-17 2016-05-24 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
US9850183B2 (en) 2014-06-27 2017-12-26 Reiley Pharmaceuticals, Inc. Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging
EP3242688B1 (en) 2015-01-09 2020-01-29 Reiley Pharmaceuticals, Inc. Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
EP3805761A4 (en) * 2018-06-08 2022-04-27 Kyungpook National University Industry-Academic Cooperation Foundation COMPOSITION FOR DIAGNOSIS OF DISEASES ASSOCIATED WITH COX2 OVEREXPRESSION AND SCREENING METHODS THEREOF

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045303A (en) * 1985-05-17 1991-09-03 Neorx Corporation Radiohalogenated small molecules for protein labeling
IL84944A (en) * 1987-01-19 1992-02-16 Ici Plc Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
EP0759432A1 (en) * 1993-01-15 1997-02-26 G.D. Searle & Co. Use of medicaments containing 3,4-diaryl furans and analogs thereof for treating a skin-related condition
US5409944A (en) * 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
WO1994026731A1 (en) * 1993-05-13 1994-11-24 Merck Frosst Canada Inc. 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
AU7467094A (en) * 1993-08-17 1995-03-14 Fujisawa Pharmaceutical Co., Ltd. Method of diagnosing alzheimer's disease
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
DK0924201T3 (da) * 1993-11-30 2002-05-21 Searle & Co Tricyclisk substitueret pyrazolylbenzensulfonamider og deres anvendelse som cyclooxygenase II-inhibitorer
US5459239A (en) * 1994-01-24 1995-10-17 Merck Frosst Canada Inc. Peptide sequences and antipeptide antisera for detecting human cyclooxygenase-1 and cyclooxygenase-2 proteins
US5393790A (en) * 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation

Also Published As

Publication number Publication date
KR19990064310A (ko) 1999-07-26
BR9611047A (pt) 2000-03-08
AU7662996A (en) 1997-05-07
CA2234633A1 (en) 1997-04-24
AU716582B2 (en) 2000-03-02
US6045773A (en) 2000-04-04
US20010055565A1 (en) 2001-12-27
EP0859642A2 (en) 1998-08-26
JP2000510816A (ja) 2000-08-22
WO1997014679A2 (en) 1997-04-24
NO981708D0 (no) 1998-04-16
WO1997014679A3 (en) 1997-08-14
NZ322674A (en) 1999-08-30

Similar Documents

Publication Publication Date Title
NO981708D0 (no) FremgangsmÕte for deteksjon av cyklooksygenase-2
NO960059L (no) Fremgangsmåte for behandling av en underjordisk formasjon
NO973635D0 (no) Fremgangsmåte for hemming av celle-celle adhesjon
NO962230L (no) Fremgangsmåte for bestemmelse av fluiders egenskaper
DE69518829D1 (de) Bestrahlungsfeldererkennungsverfahren
DE69620896D1 (de) Riefendetektionsverfahren
FI951431A (fi) Elatusaine ja menetelmä salmonellojen tunnistamiseksi
NO964479D0 (no) Fremgangsmåte for signalbehandling
NO961966L (no) Fremgangsmåte for korrigering av avviksregistrering
DE69624211D1 (de) Signalverarbeitungsverfahren
DE19531845B4 (de) Verbrennungsaussetzererkennungsverfahren
FI951472A0 (fi) Radiometri ja menetelmä veden ilmaisemiseksi
DK0810923T3 (da) Fremgangsmåde til trykning
NO943532L (no) Fremgangsmåte for måling av vannhastighet
NO944736D0 (no) Fremgangsmåte for bestemmelse av blodhastighet
FI963863A0 (fi) Analyyttinen toteaminen
NO975699L (no) Fremgangsmåte for oksyklorering
FI973500A0 (fi) 3-pyrrolidylideeni-2-oni-kefalosporiinien johdannaiset
NO954829L (no) Fremgangsmåte for representasjon av seismisk informasjon
NO964083D0 (no) Påvisning av analytter
NO971753L (no) Fremgangsmåte for selektiv fraskillelse av morfolin
NO960391D0 (no) Fremgangsmåte for utvinning av fiskemel
UA24720A (uk) Спосіб алотраhсплаhтації hирки
UA25110A (uk) Спосіб біліосорбції
UA25946C2 (uk) Спосіб одержаhhя гліцираму

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application